NCT04150913View on ClinicalTrials.gov

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

October 30, 2023

Study Completion Date

October 31, 2024

Conditions
Non Hodgkin LymphomaRefractory Non-Hodgkin LymphomaRelapsed Non Hodgkin LymphomaNeurotoxicityNeurotoxicity SyndromesCytokine Release Syndrome
Interventions
DRUG

Anakinra

Subcutaneous, dosage per protocol. Day 0 through Day 6.

DRUG

Axicabtagene Ciloleucel

Once, intravenous infusion, dosage per protocol

Trial Locations (2)

02115

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Kite, A Gilead Company

INDUSTRY

lead

Marcela V. Maus, M.D.,Ph.D.

OTHER

NCT04150913 - A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity | Biotech Hunter | Biotech Hunter